Treatment of uncommon sites of focal primary hyperhidrosis: experience with pharmacological therapy using oxybutynin

Detalhes bibliográficos
Autor(a) principal: Teivelis, Marcelo Passos
Data de Publicação: 2014
Outros Autores: Wolosker, Nelson, Krutman, Mariana, Kauffman, Paulo, de Campos, José Ribas Milanez, Puech-Leão, Pedro
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Clinics
Texto Completo: https://www.revistas.usp.br/clinics/article/view/87042
Resumo: OBJECTIVES: Primary hyperhidrosis usually affects the hands, armpits, feet and cranio-facial region. Sweating in other areas is common in secondary hyperhidrosis (after surgery or in specific clinical conditions). Oxybutynin has provided good results and is an alternative for treating hyperhidrosis at common sites. Our aim was to evaluate the efficacy of oxybutynin as a treatment for primary sweating at uncommon sites (e.g., the back and groin). METHODS: This retrospective study analyzed 20 patients (10 females) who received oxybutynin for primary focal hyperhidrosis at uncommon sites. The subjects were evaluated to determine quality of life before beginning oxybutynin and six weeks afterward and they were assigned grades (on a scale from 0 to 10) to measure their improvement at each site of excessive sweating after six weeks and at the last consult. RESULTS: The median follow-up time with oxybutynin was 385 days (133-1526 days). The most common sites were the back (n = 7) and groin (n = 5). After six weeks, the quality of life improved in 85% of the subjects. Dry mouth was very common and was reported by 16 patients, 12 of whom reported moderate/severe dry mouth. Five patients stopped treatment (two: unbearable dry mouth, two: excessive somnolence and one: palpitations). At the last visit, 80% of patients presented with moderate/great improvement at the main sites of sweating. CONCLUSION: After six weeks, more than 80% of the patients presented with improvements in their overall quality of life and at the most important site of sweating. Side effects were common (80% reported at least one side effect) and caused 25% of the patients to discontinue treatment. Oxybutynin is effective for treating bothersome hyperhidrosis, even at atypical locations and most patients cope well with the side effects.
id USP-19_f2132010b688d1491352d22530822d8a
oai_identifier_str oai:revistas.usp.br:article/87042
network_acronym_str USP-19
network_name_str Clinics
repository_id_str
spelling Treatment of uncommon sites of focal primary hyperhidrosis: experience with pharmacological therapy using oxybutynin OBJECTIVES: Primary hyperhidrosis usually affects the hands, armpits, feet and cranio-facial region. Sweating in other areas is common in secondary hyperhidrosis (after surgery or in specific clinical conditions). Oxybutynin has provided good results and is an alternative for treating hyperhidrosis at common sites. Our aim was to evaluate the efficacy of oxybutynin as a treatment for primary sweating at uncommon sites (e.g., the back and groin). METHODS: This retrospective study analyzed 20 patients (10 females) who received oxybutynin for primary focal hyperhidrosis at uncommon sites. The subjects were evaluated to determine quality of life before beginning oxybutynin and six weeks afterward and they were assigned grades (on a scale from 0 to 10) to measure their improvement at each site of excessive sweating after six weeks and at the last consult. RESULTS: The median follow-up time with oxybutynin was 385 days (133-1526 days). The most common sites were the back (n = 7) and groin (n = 5). After six weeks, the quality of life improved in 85% of the subjects. Dry mouth was very common and was reported by 16 patients, 12 of whom reported moderate/severe dry mouth. Five patients stopped treatment (two: unbearable dry mouth, two: excessive somnolence and one: palpitations). At the last visit, 80% of patients presented with moderate/great improvement at the main sites of sweating. CONCLUSION: After six weeks, more than 80% of the patients presented with improvements in their overall quality of life and at the most important site of sweating. Side effects were common (80% reported at least one side effect) and caused 25% of the patients to discontinue treatment. Oxybutynin is effective for treating bothersome hyperhidrosis, even at atypical locations and most patients cope well with the side effects. Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2014-09-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/8704210.6061/clinics/2014(09)06Clinics; Vol. 69 No. 9 (2014); 608-614Clinics; v. 69 n. 9 (2014); 608-614Clinics; Vol. 69 Núm. 9 (2014); 608-6141980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/87042/90011Copyright (c) 2014 Clinicsinfo:eu-repo/semantics/openAccessTeivelis, Marcelo Passos Wolosker, Nelson Krutman, Mariana Kauffman, Paulo de Campos, José Ribas Milanez Puech-Leão, Pedro 2014-11-04T18:02:27Zoai:revistas.usp.br:article/87042Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2014-11-04T18:02:27Clinics - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Treatment of uncommon sites of focal primary hyperhidrosis: experience with pharmacological therapy using oxybutynin
title Treatment of uncommon sites of focal primary hyperhidrosis: experience with pharmacological therapy using oxybutynin
spellingShingle Treatment of uncommon sites of focal primary hyperhidrosis: experience with pharmacological therapy using oxybutynin
Teivelis, Marcelo Passos
title_short Treatment of uncommon sites of focal primary hyperhidrosis: experience with pharmacological therapy using oxybutynin
title_full Treatment of uncommon sites of focal primary hyperhidrosis: experience with pharmacological therapy using oxybutynin
title_fullStr Treatment of uncommon sites of focal primary hyperhidrosis: experience with pharmacological therapy using oxybutynin
title_full_unstemmed Treatment of uncommon sites of focal primary hyperhidrosis: experience with pharmacological therapy using oxybutynin
title_sort Treatment of uncommon sites of focal primary hyperhidrosis: experience with pharmacological therapy using oxybutynin
author Teivelis, Marcelo Passos
author_facet Teivelis, Marcelo Passos
Wolosker, Nelson
Krutman, Mariana
Kauffman, Paulo
de Campos, José Ribas Milanez
Puech-Leão, Pedro
author_role author
author2 Wolosker, Nelson
Krutman, Mariana
Kauffman, Paulo
de Campos, José Ribas Milanez
Puech-Leão, Pedro
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Teivelis, Marcelo Passos
Wolosker, Nelson
Krutman, Mariana
Kauffman, Paulo
de Campos, José Ribas Milanez
Puech-Leão, Pedro
description OBJECTIVES: Primary hyperhidrosis usually affects the hands, armpits, feet and cranio-facial region. Sweating in other areas is common in secondary hyperhidrosis (after surgery or in specific clinical conditions). Oxybutynin has provided good results and is an alternative for treating hyperhidrosis at common sites. Our aim was to evaluate the efficacy of oxybutynin as a treatment for primary sweating at uncommon sites (e.g., the back and groin). METHODS: This retrospective study analyzed 20 patients (10 females) who received oxybutynin for primary focal hyperhidrosis at uncommon sites. The subjects were evaluated to determine quality of life before beginning oxybutynin and six weeks afterward and they were assigned grades (on a scale from 0 to 10) to measure their improvement at each site of excessive sweating after six weeks and at the last consult. RESULTS: The median follow-up time with oxybutynin was 385 days (133-1526 days). The most common sites were the back (n = 7) and groin (n = 5). After six weeks, the quality of life improved in 85% of the subjects. Dry mouth was very common and was reported by 16 patients, 12 of whom reported moderate/severe dry mouth. Five patients stopped treatment (two: unbearable dry mouth, two: excessive somnolence and one: palpitations). At the last visit, 80% of patients presented with moderate/great improvement at the main sites of sweating. CONCLUSION: After six weeks, more than 80% of the patients presented with improvements in their overall quality of life and at the most important site of sweating. Side effects were common (80% reported at least one side effect) and caused 25% of the patients to discontinue treatment. Oxybutynin is effective for treating bothersome hyperhidrosis, even at atypical locations and most patients cope well with the side effects.
publishDate 2014
dc.date.none.fl_str_mv 2014-09-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/clinics/article/view/87042
10.6061/clinics/2014(09)06
url https://www.revistas.usp.br/clinics/article/view/87042
identifier_str_mv 10.6061/clinics/2014(09)06
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/clinics/article/view/87042/90011
dc.rights.driver.fl_str_mv Copyright (c) 2014 Clinics
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2014 Clinics
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
dc.source.none.fl_str_mv Clinics; Vol. 69 No. 9 (2014); 608-614
Clinics; v. 69 n. 9 (2014); 608-614
Clinics; Vol. 69 Núm. 9 (2014); 608-614
1980-5322
1807-5932
reponame:Clinics
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Clinics
collection Clinics
repository.name.fl_str_mv Clinics - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||clinics@hc.fm.usp.br
_version_ 1800222761261465600